The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Pathways of Addiction: Opportunities in Drug Abuse Research
Van Stelle KR, Mauser E, Moberg DP. 1994. Recidivism to the criminal justice system of substance-abusing offenders diverted into treatment. Crime and Delinquency 40:175-196.
Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. 1992. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 46:876-880.
Washton AM. 1989. Cocaine Addiction: Treatment, Recovery and Relapse Prevention. New York: W. W. Norton.
Weisner C, Schmidt L. 1992. Gender disparities in treatment for alcohol problems. Journal of the American Medical Association 268(14):1872-1876.
WHO (World Health Organization). 1992. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva: WHO.
Woody G, Cacciola J. 1994. Review of remission criteria. In: Widiger T, Frances A, Pincus H, First M, Ross R, Davis W, eds. DSM-IV Sourcebook, Vol. 1. Washington, DC: American Psychiatric Association Press. Pp. 81-92.
Woody GE, Luborsky L, McLellan AT, O'Brien CP, Beck AT, Blaine J, Herman I, Hole A. 1983. Psychotherapy for opiate addicts: Does it help? Archives of General Psychiatry 40:639-645.
Woody GE, McLellan AT, Luborsky L, O'Brien CP, Blaine J, Fox S, Herman I, Beck AT. 1984. Psychiatric severity as a predictor of benefits from psychotherapy: The Penn-VA study. American Journal of Psychiatry 141:1172-1177.
Woody GE, McLellan AT, Bedrick J. 1995a. Dual diagnosis. Annual Review of Psychiatry 14:83-104.
Woody GE, McLellan AT, Luborsky L, O'Brien CP. 1995b. Psychotherapy in community methadone programs: A validation study. American Journal of Psychiatry 159:1302-1308.
Woody GE, McNicholas LF, Vocci F, eds. 1996. Guidelines for Research Involving Medications for the Treatment of Drug Addiction. Accepted by the Pilot Drug Evaluation Program and under review by the Food and Drug Administration.